|Bid||3.9500 x 1100|
|Ask||3.9800 x 800|
|Day's Range||3.9400 - 4.0800|
|52 Week Range||3.4000 - 5.6900|
|Beta (5Y Monthly)||2.08|
|PE Ratio (TTM)||10.37|
|Earnings Date||Mar 07, 2022 - Mar 11, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.00|
WALTHAM, Mass., May 16, 2022--La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three months ended March 31, 2022 and highlighted corporate progress.
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 0% and 11.60%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 40.23% and 548.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?